More Clarity Pharmaceuticals Ltd. news
Clarity Pharmaceuticals Ltd.ASX: CU6

Positive Guidance from FDA on Phase 3 Prostate Cancer Trial

Jul 3, 2023 at 10:41 PM EDT · Issued by Clarity Pharmaceuticals Ltd.

Filed with ASX · Jul 3, 2023 at 10:41 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/positive-guidance-from-fda-on-phase-3-prostate-cancer-trial

Clarity Pharmaceuticals Ltd. on 6ix

Story so far

  • COMBAT theranostic prostate cancer trial commences in the USJun 20, 2023
  • Recruitment complete for Phase II prostate cancer trialJun 7, 2023
  • Theranostic prostate cancer trial advances to cohort 2May 24, 2023

Earlier from Clarity Pharmaceuticals

  • Clarity Establishes US Center of Excellence for ResearchJun 27, 2023
  • Northstar Achieves Key Production MilestonesJun 26, 2023
  • COMBAT theranostic prostate cancer trial commences in the USJun 19, 2023
  • Clarity expands supply of Cu-64 for Phase III trialsJun 13, 2023
  • Presentation at Jefferies Healthcare ConferenceJun 12, 2023

Later from Clarity Pharmaceuticals

  • Phase II SABRE prostate cancer trial reaches 50% recruitmentJul 23, 2023
  • Final Cohort opens for CL04 Paediatric Neuroblastoma trialJul 25, 2023
  • Clarity Bolsters Antibody Pre-Targeting with IP from MSKAug 6, 2023
  • Theranostic prostate cancer trial advances to cohort 3Aug 9, 2023
  • First PC participant treated at the highest dose levelAug 24, 2023
All Clarity Pharmaceuticals news releases↗

Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.

Follow Clarity Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer